Smart & Biggar

Problem viewing? Click to view online

 
Twitter
LinkedIn
Forward
 
 
 

September 2018

 
 

Certificates of Supplementary Protection – Transitional Period Ending on September 21, 2018

 
 
Daphne C. Lainson

Daphne C. Lainson
dclainson@smart-biggar.ca

 
 

Patentees take note: September 21, 2018 marks the first anniversary of the Certificate of Supplementary Protection (CSP) regime in Canada, and it also marks the end of the transitional period for securing a CSP. As a result, the effective deadline for filing a CSP application is September 21, 2018 for applications where the first relevant foreign regulatory filing (as described below) occurred between September 21, 2016 and September 21, 2017.

A CSP is only available if the new drug submission (NDS) for a medicinal ingredient or combination of medicinal ingredients is timely filed in Canada. The NDS must be filed within a prescribed period of the filing of the first application for marketing approval of the medicinal ingredient or combination in the U.S., Europe or any member country thereof, Japan, Switzerland and Australia.  

The prescribed period is 24 months if the CSP application is filed no later than the first anniversary of the CSP regime (i.e., September 21, 2018); otherwise, the prescribed period is 12 months. If the timely NDS filing requirement is not met, the CSP application will be refused.

A CSP application is due within 120 days of the later of the grant of marketing authorization by Health Canada (i.e., a NOC) and patent grant. However, this deadline is effectively advanced to September 21, 2018 for those CSP applications that are based on an NDS filed within 12-24 months of the first application for marketing approval in any of the noted regions.   

There are other requirements for securing a CSP, as explained here. However, it is only the timely NDS filing requirement that will change after September 21, 2018.

The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.

 
 
Selected Rankings

 
 

Canadian IP Impact Case of the Year 
AstraZeneca v Apotex (NEXIUM)
LMG Life Sciences

Read more »

 

Canada’s Intellectual Property Litigation Firm of the Year
Benchmark Canada

Read more  »

 
 

EDITOR

Nancy Pei

 

     

CASE-LAW BRIEFS BY:

Andrew Mandlsohn Urszula Wojtyra Abigail Smith

Lynn Ing

Brandon Heard

Katie Lee

 

 

 

LITIGATION CONTACTS

Gunars Gaikis

Steven Garland

Sheldon Hamilton

Yoon Kang

Nancy Pei

 

Mark Biernacki

 

Jeremy Want

 

Colin Ingram

 

PROSECUTION CONTACTS

Christopher Robinson

Yoon Kang

Daphne Lainson

Thuy Nguyen

David Schwartz

 

Mark Pidkowich

 

   

REGULATORY CONTACTS

Nancy Pei

 

Alice Tseng

 

Daphne Lainson

 

 
 
 
 

OTTAWA / TORONTO / MONTREAL / VANCOUVER / CALGARY

 
 
 

UNPARALLELED IP

 
 
 

smart-biggar.ca

Twitter
LinkedIn
Forward to a Friend

The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.

 
 
 

Smart & Biggar/Fetherstonhaugh | 1100-150 York Street | Toronto | ON | M5H 3S5 | Canada
subscriptions@smart-biggar.ca
Manage Preferences | Unsubscribe
Gérer les préférences | Se désabonner